World's Best Scientists 2026 revealed!
Lidia Ruiz

Lidia Ruiz

D-Index & Metrics

Immunology

D-Index
44
Citations
8438
World Ranking
4770
National Ranking
63

Overview

Lidia Ruiz is affiliated with IrsiCaixa in Spain and has contributed extensively to the field of medicine, focusing primarily on infectious diseases and COVID-19-related research. Their work spans several subfields, including oncology, neurology, genetics, and pulmonary and respiratory medicine.

Their research predominantly addresses topics such as SARS-CoV-2 and COVID-19, including clinical studies, long-term effects, detection and testing, as well as biosensors and analytical detection techniques. Additional interests include vascular anomalies and treatments, alongside pancreatic and hepatic oncology research.

Recent publications by Lidia Ruiz reflect their involvement in COVID-19 clinical and diagnostic studies. Notable papers include:

  • Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial, 2020, Clinical Infectious Diseases
  • A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19, 2020, New England Journal of Medicine
  • SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity, 2021, Scientific Reports
  • Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial, 2021, The Lancet Infectious Diseases
  • Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test, 2021, Journal of Infection

They have frequently collaborated with several coauthors, including:

  • Bonaventura Clotet (9 joint publications)
  • Natàlia Casamitjana (5 joint publications)
  • Marc Corbacho-Monné (5 joint publications)
  • María Ubals (5 joint publications)
  • Andrea Alemany (5 joint publications)

Lidia Ruiz's work has been published in various journals and venues, such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • EDULEARN proceedings
  • Clinical Infectious Diseases
  • New England Journal of Medicine
  • Scientific Reports

The scientist's scholarly contributions center on advancing understanding and treatment options in infectious diseases, particularly focusing on the COVID-19 pandemic. Their interdisciplinary approach integrates clinical research with analytical detection technologies, aiming to address challenges in diagnosis and long-term patient outcomes.

Best Publications

  • Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

    Jacques Fellay;Catia Marzolini;Emma R. Meaden;David J. Back

  • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

    Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö

  • Chemokines and receptors in HIV encephalitis.

    Virginia J. Sanders;Christopher A. Pittman;Michael G. White;Guoji Wang

  • Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

    Cristina Tural;Lidia Ruiz;Christopher Holtzer;Jonathan Schapiro

  • Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.

    Rika Draenert;Sylvie Le Gall;Katja J. Pfafferott;Alasdair J. Leslie

  • Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.

    Albert Tuldra;Carmina R. Fumaz;Ma José Ferrer;Ramon Bayes

  • Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.

    Oriol Mitjà;Marc Corbacho-Monné;Maria Ubals;Cristian Tebe

  • Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

    Jurgen Vercauteren;Annemarie M. J. Wensing;David A. M. C. van de Vijver;Jan Albert

  • Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.

    Mónica Gumá;Cecilia Cabrera;Itziar Erkizia;Margarita Bofill

  • A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.

    Oriol Mitjà;Marc Corbacho-Monné;Maria Ubals;Andrea Alemany

  • Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

    Lidia Ruiz;Javier Martinez-Picado;Joan Romeu;Roger Paredes

  • Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

    L Ruiz;E Negredo;P Domingo;R Paredes

  • Long-Lasting Remission of Cytomegalovirus Retinitis without Maintenance Therapy in Human Immunodeficiency Virus-Infected Patients

    C. Tural;J. Romeu;G. Sirera;D. Andreu

  • Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.

    Eugenia Negredo;Luís Cruz;Roger Paredes;Lidia Ruiz

  • Secretion of interferon-γ by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18

    Laila Darwich;Gemma Coma;Ruth Peña;Rocio Bellido

  • Updated European recommendations for the clinical use of HIV drug resistance testing

    A. M. Vandamme;A. Sönnerborg;M. Ait-Khaled;J. Albert

  • HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

    Lidia Ruiz;Guislaine Carcelain;Javier Martinez-Picado;Simon Frost

  • Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

    Dimitrios Paraskevis;Dimitrios Paraskevis;Oliver Pybus;Gkikas Magiorkinis;Angelos Hatzakis

  • Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

    Eugenia Negredo;José Moltó;David Burger;Pompeyo Viciana

  • Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

    Julia G Prado;Terri Wrin;Jeff Beauchaine;Lidia Ruiz

  • Virological rebound after suppression on highly active antiretroviral therapy.

    Amanda Mocroft;Lidia Ruiz;Peter Reiss;Bruno Ledergerber

  • Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

    Alessandro Cozzi-Lepri;Andrew N Phillips;Lidia Ruiz;Bonaventura Clotet

  • Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission

    Nuria Izquierdo-Useros;Julià Blanco;Itziar Erkizia;Maria Teresa Fernández-Figueras

  • The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

    David A van de Vijver;Annemarie M J Wensing;Gioacchino Angarano;Birgitta Asjö

  • Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

    Eugenia Negredo;Josep Ribalta;Roger Paredes;Raimón Ferré

  • Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).

    J C Schmit;L Ruiz;B Clotet;A Raventos

  • SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.

    Benjamin Trinité;Ferran Tarrés-Freixas;Jordi Rodon;Edwards Pradenas

  • Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

    Lidia Ruiz;Roger Paredes;Guadalupe Gómez;Joan Romeu

Frequent Co-Authors

Javier Martinez-Picado
Javier Martinez-Picado University of Vic - Central University of Catalonia
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Maurizio Zazzi
Maurizio Zazzi University of Siena
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
Kristel Van Laethem
Kristel Van Laethem Rega Institute for Medical Research
Charles A. Boucher
Charles A. Boucher Erasmus University Rotterdam
Roger Paredes
Roger Paredes University of Vic - Central University of Catalonia
Clive Loveday
Clive Loveday University College London
Andrzej Horban
Andrzej Horban Medical University of Warsaw

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, pursuing related healthcare degrees can open diverse career paths. Fields like psychiatric nursing and nurse practitioner specializations often intersect with immunological research and patient care, offering numerous opportunities.

If you're considering advancing in nursing, exploring the best pmhnp programs is a great start. These programs not only focus on psychiatric mental health but also provide strong clinical placements, essential for hands-on experience.

Affordability is a major factor when choosing a degree. Many students benefit from looking into the cheapest psych np programs, which balance cost and quality effectively. These programs can make advancing your career more accessible without compromising education standards.

Understanding the financial outlook is also important. Knowing the doctorate in nursing salary by state helps graduates plan their futures and select locations that offer the best compensation for their expertise.

For those currently practicing as a Family Nurse Practitioner, options like the fnp to acute care np bridge program provide a pathway to specialize further. This transition enhances skills applicable in acute care and immunology-related clinical settings.

Best Scientists Citing Lidia Ruiz

Trending Scientists